ABBV - AbbVie Inc.
| Previous close | 90.03 |
| Open | 91.00 |
| Bid | 92.15 x 900 |
| Ask | 92.65 x 1200 |
| Day's range | 89.60 - 92.89 |
| 52-week range | 62.55 - 97.86 |
| Volume | 13,705,720 |
| Avg. volume | 13,427,849 |
| Market cap | 163.317B |
| Beta (5Y monthly) | 0.78 |
| PE ratio (TTM) | 16.40 |
| EPS (TTM) | 5.65 |
| Earnings date | 24 Jul 2020 - 28 Jul 2020 |
| Forward dividend & yield | 4.72 (5.24%) |
| Ex-dividend date | 14 Apr 2020 |
| 1y target est | 93.69 |
- Zacks
Ironwood to Halt MD-7246 Development After Study Failure
Ironwood's (IRWD) pipeline candidate, MD-7246 fails to meet primary endpoint in a phase II study evaluating it in patients with irritable bowel syndrome with diarrhea.
- Zacks
How Trading Your Own Retirement Can Fleece Your Financial Future - May 27, 2020
From understanding your risk tolerance to maintaining emotional control, achieving your retirement goals takes a much different investing approach than regular stock trading.
- Zacks
This is Why AbbVie (ABBV) is a Great Dividend Stock
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.
- Motley Fool
Better Buy: AbbVie vs. Merck
There are plenty of reasons for investors to like big pharma stocks. They're usually resilient during economic downturns. Many of them have solid growth prospects. And nearly all of them pay dividends.
- Zacks
Zacks Value Trader Highlights: AbbVie, B&G Foods, H&R Block, Microsoft and Apple
Zacks Value Trader Highlights: AbbVie, B&G Foods, H&R Block, Microsoft and Apple
- Motley Fool
Better Buy: AbbVie vs. Eli Lilly
These two pharma companies have outpaced the market this year, but which one will perform better than the other moving forward?
- Zacks
Is AbbVie (ABBV) Stock a Solid Choice Right Now?
AbbVie (ABBV) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
- Zacks
Dr. Reddy's (RDY) Q4 Earnings Increase Y/Y, Revenues Beat
Dr. Reddy's (RDY) fourth-quarter earnings and sales increase year over year.
- Zacks
AbbVie, Interactive, Inphi, Chegg and ServiceNow highlighted as Zacks Bull and Bear of the Day
AbbVie, Interactive, Inphi, Chegg and ServiceNow highlighted as Zacks Bull and Bear of the Day
- Zacks
3 Value Stocks That Could Thrive in a Post-Pandemic World
With an economic revival in motion despite the unfavorable circumstances so far, value stocks offer the much-needed stability to one's portfolio.
- Zacks
J&J to Stop Sale of Talc-Based Baby Powder in North America
J&J (JNJ) faces thousands of lawsuits, which claim that its talc-based products, primarily its baby powders, cause cancer.
- Zacks
AbbVie (ABBV) Upgraded to Strong Buy: Here's What You Should Know
AbbVie (ABBV) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- Zacks
Has AbbVie (ABBV) Outpaced Other Medical Stocks This Year?
Is (ABBV) Outperforming Other Medical Stocks This Year?
- Stockopedia
Why this large-cap dividend could be worth a look
The compounding effects of reinvesting dividends over the long-term can be spectacular - but finding stocks to help you do it is a challenge... The present eco...
- Stockopedia
What will drive the Abbvie Inc share price higher?
Shares in Abbvie Inc (NYQ:ABBV) are currently trading at 91.47 but a key question for investors is how the economic uncertainty caused by Coronavirus will affe...
- Zacks
Is AbbVie (ABBV) a Great Value Stock Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
- Zacks
The Zacks Analyst Blog Highlights: JPMorgan Chase, AbbVie, Royal Dutch Shell, Gilead Sciences and Anthem
The Zacks Analyst Blog Highlights: JPMorgan Chase, AbbVie, Royal Dutch Shell, Gilead Sciences and Anthem
- Zacks
Top Stock Reports for JPMorgan, AbbVie & Royal Dutch Shell
Top Stock Reports for JPMorgan, AbbVie & Royal Dutch Shell
- Zacks
Pharma Stock Roundup: FDA Updates for LLY, AZN, MRK, BMY and SNY
FDA approves Lilly's (LLY) selpercatinib for RET-altered lung and thyroid cancers and AstraZeneca (AZN)/Merck's (MRK) Lynparza for new ovarian cancer use.
